The use of RNA primers to initiate mRNA synthesis in eukaryotes was first documented for an RNA virus, influenza virus. Initially thought to be a strategy used exclusively by this particular virus, RNA priming has since been linked to synthesis of two other viral mRNAs --those of coronavirus and bunyavirus --and to synthesis of cellular mRNAs in trypanosomes. The various priming mechanisms used in these systems are considered below.
RNA Priming in Viral Systems
Influenza virus has a segmented RNA genome of negative strand polarity. The virus encodes and packages an enzyme system that synthesizes the viral mRNAs, but this system requires small, capped cellular RNA primers in order to initiate on the genomic RNA template (for review, see Krug, Curr. Topics in Microbiol. and Immunol. 93, 125-150, 1981) .
Addition of RNAs containing 5'terminal cap 1 structures (mTGpppXm) stimulates viral mRNA synthesis in vitro as much as 100-fold. A cap-dependent viral endonuclease cleaves the added RNAs at a purine residue 10-13 nucleotides from the cap (Plotch et al., Cell 23, [847] [848] [849] [850] [851] [852] [853] [854] [855] [856] [857] [858] 1981) .
The resulting capped RNA fragments serve as primers, which become covalently linked to the viral mRNAs (see figure) . There are no strong sequence requirements for priming. The only presumed hydrogen bonding involves a single base pair: the 3' terminal A of the primer and the 3' terminal U of the viral RNAs. Rather, the most important feature of the primer is its 5' cap 1 structure; both methyl groups of the cap are essential for priming activity. Cap recognition is mediated by one of the proteins associated with the viral nucleocapsids, the PB2 protein (Ulmanen et al., PNAS 78, 7355-7359, 1981; Braam et al., Cell 34, 609-618, 1983) .
Newly synthesized RNA polymerase II transcripts are used as primers in the nucleus of influenza virus-infected cells (Herz et al., Cell 26, 391-400, 1981) . Viral mRNA synthesis thus requires the continuous functioning of this cellular polymerase and is inhibited by e-amanitin. It has recently been reported that bunyavirus, another negative strand RNA virus, also uses capped cellular RNA primers; in this case, however, priming apparently occurs in the cytoplasm and does not require continuous polymerase II function (Patterson et al., J. Virol. 52, 215-222, 1984) .
In contrast to the RNA primers used by influenza virus, those used by coronavirus are virus-coded rather than host-coded. During infection, the coronaviral genomic RNA (a single 18 kb RNA of positive polarity) is first copied by a viral polymerase to form one genome-sized negative strand RNA (Lai et al., J. Virol. 44, [487] [488] [489] [490] [491] [492] 1982) . This negative strand RNA is then transcribed to form a nested set of seven subgenomic RNAs, all overlapping in sequence with the 3' end of the genomic RNA (Lai et al., J.
Virol. 39, 823-834, 1981; Spaan et al., J. Virol. 42, 432-439, 1982) . The mRNAs contain a common 5' leader sequence (Ir) of about 70 nucleotides that is probably transcribed from the 3' end of the negative strand RNA template (Lai et al., PNAS 81, [3626] [3627] [3628] [3629] [3630] 1984) . Ultraviolet light mapping studies have virtually eliminated the possibility of RNA splicing (Jacobs et al., J. Virol. 39, [401] [402] [403] [404] [405] [406] 1981) .
The most likely alternative explanation is that the leader RNA acts as a primer at various sites along the negative strand RNA to initiate synthesis of each mRNA (see figure) .
The intergenic regions preceding three of the mRNAs share a common 11 nucleotide sequence, the first 6 nucleotides of which are complementary to the 3' terminus of the leader RNA (Budzilowicz et al., J. Virol. 53, [834] [835] [836] [837] [838] [839] [840] 1985) . By itself, this short stretch of hydrogen bonding is probably not sufficient to promote primer binding. It may be that the leader RNA binds to the conserved region as part of a complex containing the viral polymerase. This interaction would stabilize the short region of hydrogen bonding, thereby aligning the leader at the proper position for priming.
Unusual Features of Trypanosome mRNAs
The 5' ends of many, if not all, mRNAs in trypanosomes contain an identical 35 nucleotide sequence. This conserved sequence was first identified in the mRNAs coding for the variant surface glycoproteins (VSGs), but has subsequently been found in all other trypanosome mRNAs examined (Parsons et al., Cell 38, 309-316, 1984) . It is encoded by a mini-exon of 1.35 kb, which is found predominantly in long tandem repeats (DeLange et al.,
Cell 34, [891] [892] [893] [894] [895] [896] [897] [898] [899] [900] 1983) . The mini-exon sequences are not linked to the sequences comprising the mRNA body; in fact, one expressed VSG gene is located on a chromosome that lacks the mini-exon (Van der Ploeg et at., Cell 39, [213] [214] [215] [216] [217] [218] [219] [220] [221] 1984) . Because of this unusual feature, the 35 conserved 5' terminal nucleotides have been termed the spliced leader (SL).
The major transcript from the mini-exon of T. brucei is a 135-141 nucleotide RNA containing the SL at its 5' end (Milhausen et al., Cell 38, 721-729, 1984; Campbell et al., Nature 311, 350-355, 1984) ; this RNA is transcribed at a 750-fold higher rate than is RNA from the rest of the miniexon (Kooter et al., EMBO J. 3, 2387 EMBO J. 3, -2392 EMBO J. 3, , 1984 . These results indicate that the small SL-containing transcript and the mRNA body are synthesized as discrete products rather than as a single large precursor RNA.
Models for Trypanosome mRNA Synthesis
How might the sequences in these two discrete RNAs be joined together? Sequence data suggest that pre-mRNA splicing is probably involved at some point. The SL sequence in the 136-141 nucleotide mini-exon transcript (and in comparable transcripts of other trypanosome species) is followed by a GU nucleotide pair, as expected for ~.,,.,,,,,,,,, One possibility is that the joining of the SL to the mRNA body is achieved in one step by intermolecular splicing (splicing in which the exons originate on two separate RNA molecules), a reaction for which there is no known precedent. This model predicts that the sequences which are 3' to the SL in the small mini-exon RNA would not be present in mRNA precursors. The other possibility is that splicing occurs after the mini-exon RNA is joined to the RNA transcript containing the mRNA body. The joining of the two RNAs could occur posttranscriptionally (by RNA ligation) or during transcription as a result of priming by either the intact mini-exon RNA or a cleavage product derived from it. If the mini-exon RNA were cleaved, it would have to occur at a position 3' to the GU following the SL, in order to preserve the 5' splice site. This model predicts that the sequences which are 3' to the SL in the small miniexon RNA would be present in mRNA precursors.
Comparisons between mRNA Synthesis in the Viral

Systems and in Trypanosomes
The priming mechanisms in the viral systems involve little or no hydrogen-bonding between the primer and the template. With influenza virus, RNA priming is mediated solely by a specific RNA-protein interaction between the cap and a viral protein. Conceivably, the same type of interaction could occur in trypanosomes, provided that the small mini-exon RNA was the only RNA containing a de novo synthesized cap.
With coronavirus, where a small amount of hydrogen bonding seems to be involved, priming again may require specific RNA-protein interactions --in this case, between the viral RNA polymerase and sequences in the leader and template RNAs. If a comparable situation existed in trypanosomes, one might expect each expressed gene to be preceded by a short common sequence that is complementary to a sequence in the small mini-exon RNA. So far, such a sequence has not been found. One major difficulty is that transcription of trypanosome genes may start far upstream of the sequences specifying the mRNA body. In fact, for one VSG gene, this start is probably greater than 8.5 kb upstream (Bernards et al., MCB 5, 545-553, 1985) . Thus, further sequence analysis of trypanosome genes will not necessarily provide further information about the role of RNA priming in this system.
The absence of linkage between the mini-exon gene and the genes specifying the trypanosome mRNA body is more analogous to the influenza model than to the coronavirus model. In the latter system, the viral polymerase is presumed to carry out all the steps in viral mRNA synthesis: synthesis of the primer, recognition of the primer binding sites, and subsequent elongation of the viral mRNAs. In contrast, the influenza viral polymerase transcribes only the mRNA bodies while a cellular enzyme, RNA polymerase II, transcribes the primers. Inhibitor studies suggest that different polymerases may be involved in synthesis of the trypanosome mRNA components: transcription of mini-exon and mRNA body sequences in isolated nuclei exhibit different ~-amanitin sensitivities (Kooter and Borst, NAR 12, 9457-9472, 1984) .
Definitive proof that RNA priming is involved in trypanosome mRNA synthesis will require the development of in vitro systems that can faithfully synthesize (initiate and elongate) the transcripts containing the mini-exon and mRNA body sequences, and catalyze joining of the SL to the mRNA bodies. Should priming be shown to operate, this would be yet another example of the relevance of viral transcription mechanisms to cellular transcription.
